Horby PW, Estcourt L, Peto L, et al. - This study (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) was conducted to assess whether convalescent plasma therapy has safety as well as efficacy for treating patients admitted to hospital with COVID-19. A total of 1,1558 (71%) eligible patients were assigned to either the convalescent plasma group or the usual care group. Twenty-eight day mortality, analysed on an intention-to-treat basis, was the primary outcome. According to findings, no improvement in survival or other prespecified clinical outcomes was conferred by high-titre convalescent plasma in this study population.